Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00765726 · ClinicalTrials.gov registry record · Phase 4
Study Evaluating The Safety Of Xyntha In Usual Care Settings
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT00765726 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT00765726, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to collect safety information associated with the use of Xyntha in a usual care setting. Upon meeting eligibility criteria, patients will be required to have approximately 5 study visits over a 2 year period. Procedures completed throughout the study include collection of vital signs, physical exams, and laboratory assessments. Patients will be required to complete an infusion log for each Xyntha infusion.
Interventions
- BIOLOGICAL Moroctocog alfa(AF-CC)
- PROCEDURE Blood draw for laboratory testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-02 |
| Est. Completion | 2011-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00765726
The ClinicalTrials.gov registry entry for NCT00765726 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Moroctocog alfa(AF-CC) is the first listed.
NCT00765726 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00765726 about?
NCT00765726 is a clinical study titled "Study Evaluating The Safety Of Xyntha In Usual Care Settings". The purpose of this study is to collect safety information associated with the use of Xyntha in a usual care setting. Upon meeting eligibility criteria, patients will be required to have approximately 5 study visits over a 2 year period. Procedures completed throughout the study include collection o...
What is the current status of trial NCT00765726?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2009-02. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00765726?
The interventions under investigation include: Moroctocog alfa(AF-CC) (BIOLOGICAL), Blood draw for laboratory testing (PROCEDURE).
Who is sponsoring clinical trial NCT00765726?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.